CY1105910T1 - ΝΕΥΡΟΠΡΟΣΤΑΤΕΥΤΙΚΕΣ ΙΔΙΟΤΗΤΕΣ ΤΟΥ GDF-15, ΕΝΟΣ ΜΕΛΟΥΣ ΤΗΣ ΥΠEPΟΙΚΟΓΕΝΕΙΑΣ ΤΩΝ TGF-β - Google Patents

ΝΕΥΡΟΠΡΟΣΤΑΤΕΥΤΙΚΕΣ ΙΔΙΟΤΗΤΕΣ ΤΟΥ GDF-15, ΕΝΟΣ ΜΕΛΟΥΣ ΤΗΣ ΥΠEPΟΙΚΟΓΕΝΕΙΑΣ ΤΩΝ TGF-β

Info

Publication number
CY1105910T1
CY1105910T1 CY20071100023T CY071100023T CY1105910T1 CY 1105910 T1 CY1105910 T1 CY 1105910T1 CY 20071100023 T CY20071100023 T CY 20071100023T CY 071100023 T CY071100023 T CY 071100023T CY 1105910 T1 CY1105910 T1 CY 1105910T1
Authority
CY
Cyprus
Prior art keywords
protein
nucleic acids
tgf
vector
gdf
Prior art date
Application number
CY20071100023T
Other languages
English (en)
Inventor
Klaus Unsicker
Kerstin Krieglstein
Original Assignee
Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh filed Critical Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh
Publication of CY1105910T1 publication Critical patent/CY1105910T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Eye Examination Apparatus (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με την τροποποίηση μίας πρωτεΐνης δίκην αυξητικού παράγοντα-βήτα (TGF-β), που προέρχεται από νευρώνες και κύτταρα νευρογλοίας, και η οποία έχει μία νευροτροφική επίδραση στους ντοπαμινεργικούς νευρώνες (DAergic), με τα νουκλεϊκά οξέα που κωδικοποιούν αυτή την πρωτεΐνη, με τον φορέα που περιέχει αυτά τα νουκλεϊκά οξέα, με τους ξενιστές οργανισμούς που περιέχουν τα νουκλεϊκά οξέα ή τον φορέα, με τα αντισώματα που στοχεύουν έναντι της πρωτεΐνης, με τις μεθόδους για την παραγωγή των νουκλεϊκών οξέων, του φορέα ή της πρωτεΐνης, με μία φαρμακευτική σύνθεση για την θεραπεία των νευροεκφυλιστικών διαταραχών στα θηλαστικά και με ένα διαγνωστικό κιτ για την ανίχνευση των εν λόγω διαταραχών.
CY20071100023T 1999-05-17 2007-01-08 ΝΕΥΡΟΠΡΟΣΤΑΤΕΥΤΙΚΕΣ ΙΔΙΟΤΗΤΕΣ ΤΟΥ GDF-15, ΕΝΟΣ ΜΕΛΟΥΣ ΤΗΣ ΥΠEPΟΙΚΟΓΕΝΕΙΑΣ ΤΩΝ TGF-β CY1105910T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99109714 1999-05-17
EP99114853 1999-07-29
EP00935043A EP1179067B1 (en) 1999-05-17 2000-05-16 Neuroprotective properties of gdf-15, a member of the tgf-beta superfamily
PCT/EP2000/004445 WO2000070051A1 (en) 1999-05-17 2000-05-16 NEUROPROTECTIVE PROPERTIES OF GDF-15, A NOVEL MEMBER OF THE TGF-β SUPERFAMILY

Publications (1)

Publication Number Publication Date
CY1105910T1 true CY1105910T1 (el) 2011-02-02

Family

ID=26153004

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100023T CY1105910T1 (el) 1999-05-17 2007-01-08 ΝΕΥΡΟΠΡΟΣΤΑΤΕΥΤΙΚΕΣ ΙΔΙΟΤΗΤΕΣ ΤΟΥ GDF-15, ΕΝΟΣ ΜΕΛΟΥΣ ΤΗΣ ΥΠEPΟΙΚΟΓΕΝΕΙΑΣ ΤΩΝ TGF-β

Country Status (12)

Country Link
US (1) US20060148709A1 (el)
EP (1) EP1179067B1 (el)
JP (1) JP2002543841A (el)
AT (1) ATE348164T1 (el)
AU (1) AU5067100A (el)
CA (1) CA2372119A1 (el)
CY (1) CY1105910T1 (el)
DE (1) DE60032355T2 (el)
DK (1) DK1179067T3 (el)
ES (1) ES2275513T3 (el)
PT (1) PT1179067E (el)
WO (1) WO2000070051A1 (el)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2300325T3 (es) 2000-04-20 2008-06-16 St Vincent's Hospital Sydney Limited Ensayo diagnostico que implica la citoquina 1 inhibitoria de macrofagos (mc1).
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2390820A1 (en) 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
EP1884777A1 (en) * 2006-08-04 2008-02-06 Medizinische Hochschule Hannover Means and methods for assessing the risk of cardiac interventions based on GDF-15
KR101245877B1 (ko) 2006-08-04 2013-03-20 메디치니쉐 호흐슐레 하노버 Ｇｄｆ-15 를 바탕으로 한, 심장 중재의 위험도를 평가하는수단 및 방법
CN100588717C (zh) * 2007-03-21 2010-02-10 中国医学科学院阜外心血管病医院 生长分化因子15基因多态位点在预测高血压继发左心室肥厚中的用途
JP2011501112A (ja) 2007-10-10 2011-01-06 エフ．ホフマン−ラ ロシュ アーゲー 心筋梗塞のモニタリング及びその治療のための手段及び方法
EP2103943A1 (en) 2008-03-20 2009-09-23 F. Hoffman-la Roche AG GDF-15 for assessing a cardiovascular risk with respect to the administration of antiinflammatory drugs
CN102203619B (zh) 2008-10-31 2015-12-16 圣文森特医院悉尼有限公司 慢性肾病中的预测方法
KR20100054711A (ko) * 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
EP2209003A1 (en) 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
EP2211182A1 (en) 2009-01-16 2010-07-28 Roche Diagnostics GmbH Method for the assessment of severity of liver cirrhosis
ES2579953T3 (es) 2009-09-17 2016-08-17 Roche Diagnostics Gmbh Panel multimarcador para la hipertrofia del ventrículo izquierdo
ES2647461T3 (es) 2009-12-18 2017-12-21 F. Hoffmann-La Roche Ag GDF-15 y/o troponina T para predecir insuficiencia renal en pacientes con cirugía cardíaca
JP5224308B2 (ja) * 2010-02-22 2013-07-03 公立大学法人横浜市立大学 卵巣明細胞腺癌に特異的に発現しているタンパク質とその応用
EP2388594A1 (en) 2010-05-17 2011-11-23 Roche Diagnostics GmbH GDF-15 based means and methods for survival and recovery prediction in acute inflammation
WO2012020045A1 (en) 2010-08-10 2012-02-16 Roche Diagnostics Gmbh Method for selecting patients with stable coronary artery disease for pci or medical treatment
ES2627337T3 (es) 2010-08-26 2017-07-27 F. Hoffmann-La Roche Ag Uso de biomarcadores para controlar una medicación en un sujeto que padece insuficiencia cardíaca
EP2439535A1 (en) 2010-10-07 2012-04-11 F. Hoffmann-La Roche AG Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus
WO2012066140A1 (en) 2010-11-19 2012-05-24 Roche Diagnostics Gmbh Method for monitoring physical training in healthy and diseased individuals
EP2490027A1 (en) 2011-02-15 2012-08-22 Roche Diagnostics GmbH Means and methods for diagnosing pregnancy complications based on GDF-15 and PlGF/sFlt1
WO2012146645A1 (en) 2011-04-27 2012-11-01 Roche Diagnostics Gmbh Diagnosis of kidney injury after surgery
EP2574932A1 (en) 2011-09-30 2013-04-03 Roche Diagnostics GmbH sFlt1 in subjects during or immediately after physical exercise
EP2581040A1 (en) 2011-10-10 2013-04-17 Roche Diagnostics GmbH TnT based cardiac hypertrophy risk related physiological training and guidance in athletes
BR122021026652B1 (pt) 2011-10-17 2022-08-23 F. Hoffmann-La Roche Ag Método in vitro para diagnosticar fibrilação atrial intermitente, uso de uma troponina cardíaca e dispositivo para diagnosticar fibrilação atrial intermitente
WO2013148117A1 (en) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP2597467A1 (en) 2012-06-26 2013-05-29 Roche Diagniostics GmbH Means and methods for proSP-B based diagnosis of pulmonary congestion in ACS patients
WO2014049087A1 (en) 2012-09-26 2014-04-03 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
WO2014086833A1 (en) 2012-12-04 2014-06-12 Roche Diagnostics Gmbh Biomarkers in the selection of therapy of heart failure
AU2013364133B2 (en) 2012-12-21 2018-10-11 Aveo Pharmaceuticals, Inc. Anti-GDF15 antibodies
KR101993714B1 (ko) 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
EP2843414B1 (en) 2013-08-26 2018-09-19 Roche Diagniostics GmbH Marker for statin treatment stratification in heart failure
CN105960593B (zh) 2013-11-04 2018-05-15 密歇根大学董事会 用于慢性肾病进展预测的生物标记物和方法
ES2712201T3 (es) 2014-01-28 2019-05-09 Hoffmann La Roche Biomarcadores para la evaluación de riesgos y la monitorización del tratamiento en pacientes de insuficiencia cardíaca que han recibido terapia guiada por el péptido natriurético de tipo B
RS59700B1 (sr) 2014-03-26 2020-01-31 Univ Wuerzburg J Maximilians Monoklonalna antitela za faktor 15 (gdf-15) rasta i diferencijacije, i njihove upotrebe u lečenju kancerske kaheksije i kancera
ES2676553T3 (es) 2014-03-26 2018-07-20 F. Hoffmann-La Roche Ag IGFBP7 para el diagnóstico de la disfunción diastólica
MD20170020A2 (ro) 2014-07-30 2017-07-31 Ngm Biopharmaceuticals, Inc. Compoziţii şi metode utilizate pentru tratamentul tulburărilor metabolice
JP6803833B2 (ja) 2014-10-29 2020-12-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 死亡率のリスク予測のためのバイオマーカー
CN115043945A (zh) 2014-10-31 2022-09-13 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
EA201890850A1 (ru) 2015-10-02 2018-09-28 Юлиус-Максимилианс-Универзитет Вюрцбург Комбинированное лечение с использованием ингибиторов человеческого фактора роста и дифференцировки 15 (gdf-15) и блокаторов контрольных точек иммунного ответа
DK3356827T3 (da) 2015-10-02 2024-01-08 Univ Wuerzburg J Maximilians Gdf-15 som en diagnostisk markør til forudsigelse af det kliniske resultat af en behandling med immun-checkpoint-blokkere
ES2774967T3 (es) 2015-10-08 2020-07-23 Hoffmann La Roche IGFBP7 para la predicción del riesgo de LRA cuando se mide antes de una intervención quirúrgica
CN105603093A (zh) * 2016-02-05 2016-05-25 广州复能基因有限公司 以MIC-1 cDNA为模板制备RNA探针的方法
US10174119B2 (en) 2016-03-31 2019-01-08 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
JP2021014434A (ja) * 2019-07-12 2021-02-12 国立大学法人千葉大学 うつ病またはうつ症状の予防または治療剤としてのトランスフォーミング増殖因子β１
EP3943946A1 (en) 2020-07-20 2022-01-26 F. Hoffmann-La Roche AG Gdf-15 for predicting the disease severity of a patient with covid-19
WO2022229442A2 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Presepsin marker panels for early detection of sepsis
JP2024515086A (ja) 2021-04-30 2024-04-04 エフ． ホフマン－ラ ロシュ アーゲー 敗血症の早期検出のためのｇｄｆ１５マーカーパネル
CN118043479A (zh) 2021-09-29 2024-05-14 豪夫迈·罗氏有限公司 用于脓毒症的早期检测的MR-proADM标志物组
WO2023156655A1 (en) 2022-02-21 2023-08-24 F. Hoffmann-La Roche Ag Dll1 marker panels for early detection of sepsis
WO2023175152A1 (en) 2022-03-18 2023-09-21 Roche Diagnostics Gmbh Troponin marker combinations for early discrimination of type 2 versus type 1 acute myocardial infarction
WO2023175176A1 (en) 2022-03-18 2023-09-21 Roche Diagnostics Gmbh Cmybpc marker combinations for early discrimination of type 2 versus type 1 acute myocardial infarction
CN114891086B (zh) * 2022-06-01 2024-03-26 恺佧生物科技(上海)有限公司 一种生物素标记的gdf15的复性方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180602B1 (en) * 1992-08-04 2001-01-30 Sagami Chemical Research Center Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent
US5994102A (en) * 1994-12-15 1999-11-30 Human Genome Sciences, Inc. Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
ATE423788T1 (de) * 1995-06-22 2009-03-15 St Vincents Hosp Sydney Neues tgf-beta-ahnliches cytokin
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US6524802B1 (en) * 1996-03-29 2003-02-25 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-14
JP2001500732A (ja) * 1996-09-11 2001-01-23 オーソ―マクニール・フアーマシユーチカル・インコーポレーテツド 前立腺がんを治療するためのＴＮＦ―β様タンパク質、ならびに関連する核酸分子、医薬組成物および方法
FR2761258B1 (fr) * 1997-03-26 1999-06-11 Rhone Poulenc Rorer Sa Procede de stimulation de la regeneration nerveuse
ES2214743T3 (es) * 1997-09-19 2004-09-16 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Combinacion de citocinas con actividad neurotrofica.
WO2000065028A2 (en) * 1999-04-26 2000-11-02 Stem Cell Pharmaceuticals, Inc. TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR

Also Published As

Publication number Publication date
DK1179067T3 (da) 2007-03-19
DE60032355T2 (de) 2007-04-26
PT1179067E (pt) 2007-01-31
US20060148709A1 (en) 2006-07-06
ATE348164T1 (de) 2007-01-15
AU5067100A (en) 2000-12-05
DE60032355D1 (de) 2007-01-25
EP1179067B1 (en) 2006-12-13
EP1179067A1 (en) 2002-02-13
ES2275513T3 (es) 2007-06-16
CA2372119A1 (en) 2000-11-23
JP2002543841A (ja) 2002-12-24
WO2000070051A1 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
CY1105910T1 (el) ΝΕΥΡΟΠΡΟΣΤΑΤΕΥΤΙΚΕΣ ΙΔΙΟΤΗΤΕΣ ΤΟΥ GDF-15, ΕΝΟΣ ΜΕΛΟΥΣ ΤΗΣ ΥΠEPΟΙΚΟΓΕΝΕΙΑΣ ΤΩΝ TGF-β
ATE516304T1 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
CY1105446T1 (el) Διαγνωση και θepαπεια διαταραχων που συνδεονται με aur1 και aur2
DE69839444D1 (de) Smad 6 und dessen anwendungen
TR200102497T2 (tr) Yeni streptococcus antijenleri
CY1110360T1 (el) Τροποποιημενος παραγοντας viii
AU7074698A (en) Detection and modulation of the iaps and naip for the diagnosis and treatment ofproliferative disease
CY1112330T1 (el) Πρωτεϊνες συνδεσης gag
DE69435038D1 (de) Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie
CY1105958T1 (el) Πολυαμιδικα παραγωγα νουκλεϊκου οξεως, μεσα και μεθοδοι παρασκευης τους
CY1106070T1 (el) Πολυμορφισμοι στο γονιδιο c μεταφορας οργανικου ανιοντος ανθρωπου (oatp-c) - (organic anion transporter c gene)
WO2003011898A3 (fr) Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
ATE521702T1 (de) Krebsantigene und deren nutzung
DE60127715D1 (de) Polypeptide zur auslösung einer immunreaktion gegen krebs
DK1373502T3 (da) Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf
BR0113099A (pt) Gene e proteìna relacionados com esquizofrenia
DK0845034T3 (da) Peptid med pronociceptive egenskaber
WO2001029220A3 (en) Mage-a12 antigenic peptides and uses thereof
DE69804302T2 (de) Kationische mittel zur transfektion von nukleinsäuren
AU5569600A (en) Novel protein and dna thereof
WO2002030977A3 (en) Egf motif protein, egfl6 materials and methods
FI970299A0 (fi) Oligomeeriset kantajamolekyylit, joissa on määritetysti sisällytettyjä merkitsinryhmiä ja hapteeneja
MX9606065A (es) Proteina fijadora de atp y acidos nucleicos con supuestas propiedades de helicasa y atpasa.
ES2190888B1 (es) Nuevas aplicaciones de la leptina como suplemento nutricional.
WO2003093787A3 (en) Antiproliferative protein from hypericum perforatum and nucleic acids encoding the same